Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acalisib
- Development stage
- Phase 1
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Acalisib is an investigational, oral small molecule inhibitor that selectively targets the delta isoform of phosphatidylinositol 3-kinase (PI3Kδ), an enzyme predominantly expressed in immune cells such as B-cells and T-cells. By inhibiting PI3Kδ, acalisib disrupts signaling pathways involved in cell growth, survival, and metabolism, leading to decreased tumor cell proliferation and induction of apoptosis. It has been primarily investigated for use in lymphoid malignancies and other hematological cancers. Acalisib was originally developed under the code names GS-9820 and CAL-120[1][2][3][4][5].
- Other names
- acalisib
02
Targets
PIK3CA (Phosphoinositide 3-kinase alpha)PIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3CD (Phosphatidylinositol 3-kinase delta)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)
Beyond the preview
Go deeper on acalisib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acalisib.